Macrogen operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Macrogen with three other
companies in this sector in South Korea:
sales of 22.21 billion Korean Won [US$19.90 million]
of which 52%
Seoulin Bioscience Company Limited
(44.89 billion Korean Won [US$40.22 million]
of which 94%
was Biotechnology), and
Medipost Co Ltd
(28.65 billion Korean Won [US$25.67 million]
of which 55%
was Umbilical Cord Blood).
During the year ended December of 2016, sales at
Macrogen were 91.11 billion Korean Won (US$81.64 million).
increase of 14.6%
versus 2015, when the company's sales were 79.53 billion Korean Won.
This was the fifth consecutive year of sales increases at Macrogen
(and since 2011, sales have increased a total of 181%).
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
453.5% in 2016, from
156.58 million Korean Won to 866.67 million Korean Won.
Macrogen also saw significant increases in sales in
Genome Application (up 29.0% to 4.89 billion Korean Won)